PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17564679-3	2007	In agreement with this, dibutyryl-cGMP, a permeable cGMP analogue, and atrial natriuretic peptide, a ligand for particulate guanylyl cyclase, are both able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.	dibutyryl-cGMP	24-38	glial fibrillary acidic protein	Rattus norvegicus	294-325
18684888-6	2008	We tested the effect of the membrane-permeant cGMP analog dibutyryl-cGMP (db-cGMP) on surface NKCC2 levels.	dibutyryl-cGMP	58-72	solute carrier family 12 member 1	Rattus norvegicus	94-99
17564679-3	2007	In agreement with this, dibutyryl-cGMP, a permeable cGMP analogue, and atrial natriuretic peptide, a ligand for particulate guanylyl cyclase, are both able to induce process elongation and branching in astrocytes resulting from a rapid, reversible and concentration-dependent redistribution of glial fibrillary acidic protein (GFAP) and actin filaments without significant change in protein levels.	dibutyryl-cGMP	24-38	glial fibrillary acidic protein	Rattus norvegicus	327-331
17564679-6	2007	Furthermore, dibutyryl-cGMP prevents RhoA-membrane association, a step necessary for its interaction with effectors.	dibutyryl-cGMP	13-27	ras homolog family member A	Rattus norvegicus	37-41
17452115-9	2007	The effect of NO on MMP-9 expression was mimicked by dibutyryl-cGMP and inhibited by PKG inhibitor KT5823, suggesting NO regulates MMP-9 expression via guanylate cyclase-PKG pathway.	dibutyryl-cGMP	53-67	matrix metallopeptidase 9	Rattus norvegicus	20-25
17452115-9	2007	The effect of NO on MMP-9 expression was mimicked by dibutyryl-cGMP and inhibited by PKG inhibitor KT5823, suggesting NO regulates MMP-9 expression via guanylate cyclase-PKG pathway.	dibutyryl-cGMP	53-67	matrix metallopeptidase 9	Rattus norvegicus	131-136
14566822-9	2003	The effect of dibutyryl-cGMP on COX-2 expression was similar to that of SNAP.	dibutyryl-cGMP	14-28	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
16778361-4	2006	These changes of Bax were attenuated by pretreatment with SNP at a low-nontoxic concentration (100 microM) or dibutyryl cGMP (DBcGMP), a cell-permeable cGMP analogue.	dibutyryl-cGMP	110-124	BCL2-associated X protein	Mus musculus	17-20
16390332-8	2006	Furthermore, it was observed that the inhibitory effect of Ang-(1-7) on the Na+-ATPase activity was completely reversed by 0.1 microM LY83583, an inhibitor of guanylate cyclase, and by 2 muM KT5823, a PKG (protein kinase G) inhibitor, and was mimicked by 10 nM d-cGMP (dibutyryl cGMP).	dibutyryl-cGMP	269-283	angiopoietin 1	Homo sapiens	59-67
16007171-6	2005	Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125).	dibutyryl-cGMP	12-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-50
16007171-6	2005	Addition of dibutyryl-cGMP (db-cGMP) induced COX-2 expression in a manner similar to SNAP; this induction was blocked by a p38 inhibitor (SB202190), but not by a JNK inhibitor (SP600125).	dibutyryl-cGMP	12-26	mitogen-activated protein kinase 14	Homo sapiens	123-126
1280259-10	1992	Pretreatment of cells with dibutyryl-cGMP mimicked molybdate effect on VDR reorganization.	dibutyryl-cGMP	27-41	vitamin D receptor	Homo sapiens	71-74
11833719-7	2001	Dibutyryl cGMP (db-cGMP), a cGMP analogue, mimicked the effect of SNP and CNP.	dibutyryl-cGMP	0-14	2',3'-cyclic nucleotide 3' phosphodiesterase	Bos taurus	74-77
11525437-8	2001	RESULTS: N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NOS, significantly inhibited FMLP-induced chemotaxis (P<0.01) and dibutyryl cGMP, an activator of cGMP-dependent protein kinase, significantly attenuated the inhibition by L-NAME (P<0.01).	dibutyryl-cGMP	143-157	formyl peptide receptor 1	Homo sapiens	103-107
9676724-4	1998	Indeed, dibutyryl-cGMP (10(-4) M) decreased gj by 80 +/- 3.5% (n = 15) within 90 s, and zaprinast, a selective inhibitor of cGMP phosphodiesterase, enhanced the effect of ANF on gj.	dibutyryl-cGMP	8-22	natriuretic peptide A	Homo sapiens	171-174
7662707-3	1995	Although dibutyryl cGMP (dbcGMP), a membrane-permeable derivative of cGMP, has been shown to inhibit pepsinogen secretion only stimulated by cholecystokinin (CCK), the intracellular mechanism of this effect remains unclear.	dibutyryl-cGMP	9-23	cholecystokinin	Homo sapiens	141-156
7662707-3	1995	Although dibutyryl cGMP (dbcGMP), a membrane-permeable derivative of cGMP, has been shown to inhibit pepsinogen secretion only stimulated by cholecystokinin (CCK), the intracellular mechanism of this effect remains unclear.	dibutyryl-cGMP	9-23	cholecystokinin	Homo sapiens	158-161
7662707-5	1995	Dibutyryl cGMP and sodium nitroprusside have now been shown to inhibit pepsinogen secretion induced by not only CCK octapeptide but also carbamylcholine chloride and ionomycin in a dose-dependent manner.	dibutyryl-cGMP	0-14	cholecystokinin	Homo sapiens	112-115
8020502-6	1994	An activator for cGMP-dependent protein kinase (cGK), dibutyryl cGMP, mimicked the stimulation of GH release from GH3 cells by CNP.	dibutyryl-cGMP	54-68	natriuretic peptide C	Rattus norvegicus	127-130
12021404-7	2002	Treatment with dibutyryl cGMP, but not dibutyryl cAMP, induced an increase in AQP5 levels in the APM.	dibutyryl-cGMP	15-29	aquaporin 5	Rattus norvegicus	78-82
11677240-4	2001	The membrane-permeable cGMP analog dibutyryl-cGMP attenuated the H(2)O(2)-induced decrease in cell viability, DNA ladder formation, nuclear condensation, reduction of the mitochondrial membrane potential, cytochrome c release from mitochondria, and caspase-3 activation in cultured astrocytes.	dibutyryl-cGMP	35-49	caspase 3	Rattus norvegicus	249-258
10657260-3	2000	The effect of a cGMP analogue, dibutyryl cGMP (dbcGMP), on angiotensin II-(AII) and PMA-induced MLC phosphorylation (MLCP) was tested, in the presence of calyculin A (CA), an inhibitor of MLC-PP.	dibutyryl-cGMP	31-45	angiotensinogen	Rattus norvegicus	59-73
10428055-2	1999	Treatment with dibutyryl cGMP (DBcGMP) dose-dependently increased the phosphorylation of both p44 and p42 isoforms of MAPK.	dibutyryl-cGMP	15-29	mitogen activated protein kinase 3	Rattus norvegicus	94-97
10428055-2	1999	Treatment with dibutyryl cGMP (DBcGMP) dose-dependently increased the phosphorylation of both p44 and p42 isoforms of MAPK.	dibutyryl-cGMP	15-29	mitogen activated protein kinase 3	Rattus norvegicus	118-122
9514205-4	1998	Treatment with 1 mM dibutyryl cGMP (dbcGMP) for 30 min also significantly inhibited the 5-HT- and thrombin-induced [Ca2+]i increase to approximately 60-70% of control.	dibutyryl-cGMP	20-34	coagulation factor II	Rattus norvegicus	98-106
8788938-8	1995	Dibutyryl cGMP and 8-bromo cGMP also increased the open probability of KNO1 and KNO2 in cell-attached patches.	dibutyryl-cGMP	0-14	collagen type XVIII alpha 1 chain	Homo sapiens	71-75
8788938-8	1995	Dibutyryl cGMP and 8-bromo cGMP also increased the open probability of KNO1 and KNO2 in cell-attached patches.	dibutyryl-cGMP	0-14	ADAM metallopeptidase with thrombospondin type 1 motif 18	Homo sapiens	80-84
7829983-4	1994	Whereas the abundance of POMC mRNA was found to be markedly suppressed following 4h of incubation with rANP(1-28) (0.01 to 1 microM), SNP (0.1 to 10 microM) and dibutyryl-cGMP (1 to 100 microM) in a dose related manner, only a modest reduction in the release and cell contents of beta EP-LI was found in some of these cultures.	dibutyryl-cGMP	161-175	pro-opiomelanocortin-alpha	Mus musculus	25-29
8020502-6	1994	An activator for cGMP-dependent protein kinase (cGK), dibutyryl cGMP, mimicked the stimulation of GH release from GH3 cells by CNP.	dibutyryl-cGMP	54-68	gonadotropin releasing hormone receptor	Rattus norvegicus	98-100
3384954-5	1988	The effect of CCK-8 was antagonized by dibutyryl cGMP (Bt2 cGMP) (10(-3) M), the VIP-antagonist (N-Ac-Tyr1, D-Phe2)-growth hormone-releasing factor-(1-29)-NH2, and abolished by tetrodotoxin.	dibutyryl-cGMP	39-53	cholecystokinin	Canis lupus familiaris	14-17
2563941-3	1989	The hormonal response to corticotropin-releasing factor (10(-10) mol/l), vasopressin (10(-9) mol/l) as well as KC1 (48 mmol/l) was reduced by membrane permeant analogs of cGMP, such as 8-BrcGMP and dibutyryl-cGMP.	dibutyryl-cGMP	198-212	corticotropin releasing hormone	Rattus norvegicus	25-55
2563941-3	1989	The hormonal response to corticotropin-releasing factor (10(-10) mol/l), vasopressin (10(-9) mol/l) as well as KC1 (48 mmol/l) was reduced by membrane permeant analogs of cGMP, such as 8-BrcGMP and dibutyryl-cGMP.	dibutyryl-cGMP	198-212	arginine vasopressin	Rattus norvegicus	73-84
1322053-8	1992	Dibutyryl-cGMP (10(-4) M) inhibited Isc from 33 +/- 4 to 22 +/- 3 microA/cm2 (P less than 0.05) in the presence of BK but not in its absence.	dibutyryl-cGMP	0-14	kininogen 1	Homo sapiens	115-117
2298233-5	1990	In receptor binding assays, dibutyryl cGMP competed with 125I-labeled gastrin for binding to HCT 116 cells (IC50 = 1.8 mM).	dibutyryl-cGMP	28-42	gastrin	Homo sapiens	70-77
2553626-2	1989	Dibutyryl cGMP added to HT-2 cell cultures without IL-2 or in the presence of an optimal IL-2 concentration (60 U/ml) had no effect on proliferation.	dibutyryl-cGMP	0-14	interleukin 2	Mus musculus	89-93
2992477-4	1985	Type IV collagenolytic activity appeared to be correlated positively with the cGMP/cAMP ratio, and negatively with the glucocorticoid receptor activity, and the activity was increased by the addition of dibutyryl cGMP.	dibutyryl-cGMP	203-217	nuclear receptor subfamily 3 group C member 1	Homo sapiens	119-142
3000856-6	1986	Two CCK antagonists were studied; N-carbobenzoxy-L-tryptophan was more potent than dibutyryl-cGMP.	dibutyryl-cGMP	83-97	cholecystokinin	Rattus norvegicus	4-7
2982853-2	1985	Elastin synthesis was enhanced (approximately 80%) by dibutyryl cGMP (Bt2cGMP) in concentrations ranging from 0.01 to 100 nM.	dibutyryl-cGMP	54-68	elastin	Homo sapiens	0-7
6192728-3	1983	The biological responses were inhibited by dibutyryl cGMP, a known CCK antagonist.	dibutyryl-cGMP	43-57	cholecystokinin	Canis lupus familiaris	67-70
6095678-7	1984	The CCK antagonists dibutyryl cGMP and proglumide inhibited 125I-CCK binding with an IC50 of 31 and 600 microM, respectively.	dibutyryl-cGMP	20-34	cholecystokinin	Bos taurus	4-7
6095678-7	1984	The CCK antagonists dibutyryl cGMP and proglumide inhibited 125I-CCK binding with an IC50 of 31 and 600 microM, respectively.	dibutyryl-cGMP	20-34	cholecystokinin	Bos taurus	65-68
6206732-4	1984	Dibutyryl cGMP and proglumide each inhibited the stimulation of amylase secretion caused by CCK-(27-32)-NH2.	dibutyryl-cGMP	0-14	cholecystokinin	Rattus norvegicus	92-95
6301290-3	1983	Dibutyryl cGMP inhibited the stimulation of pepsinogen secretion caused by cholecystokinin but not that caused by carbamylcholine; atropine inhibited the stimulation of pepsinogen secretion caused by carbamylcholine but not that caused by cholecystokinin.	dibutyryl-cGMP	0-14	pepsin II-2/3	Oryctolagus cuniculus	44-54
6297314-11	1983	The peptide stimulation of pepsinogen secretion was inhibited by dibutyryl cGMP, whereas stimulation of acid formation was not inhibited by the cyclic nucleotide.	dibutyryl-cGMP	65-79	pepsin II-2/3	Oryctolagus cuniculus	27-37
6301290-3	1983	Dibutyryl cGMP inhibited the stimulation of pepsinogen secretion caused by cholecystokinin but not that caused by carbamylcholine; atropine inhibited the stimulation of pepsinogen secretion caused by carbamylcholine but not that caused by cholecystokinin.	dibutyryl-cGMP	0-14	cholecystokinin	Oryctolagus cuniculus	75-90
6254515-0	1980	Dibutyryl cGMP: inhibitor of the effect of cholecystokinin and gastrin on the guinea pig gallbladder in vitro.	dibutyryl-cGMP	0-14	gastrin	Cavia porcellus	63-70
6251137-6	1980	Inhibition of LIF-induced esterolysis was also provided by dibutyryl cGMP, but only at concentrations 10(-7) to 10(-5) M; 8-bromo cGMP and adenosine 3",5"-cyclic monophosphate were both ineffective.	dibutyryl-cGMP	59-73	LIF interleukin 6 family cytokine	Homo sapiens	14-17
21738583-5	2011	In this study, we investigated the role of the F-actin cytoskeleton in the secretion of retinoschisin by treating Weri-Rb1 cells, which are known to secrete retinoschisin, with cytochalasin D, jasplakinolide, Y-27632, and dibutyryl cGMP.	dibutyryl-cGMP	222-236	retinoschisin 1	Homo sapiens	88-101
182889-2	1976	Both cGMP and dibutyryl cGMP enhanced to an equal extent platelet aggregation induced by epinephrine or by chick skin collagen alpha1 chain.	dibutyryl-cGMP	14-28	collagen type I alpha 1 chain	Gallus gallus	118-139
26887831-9	2016	In contrast, dibutyryl-cGMP significantly decreased NKCC2 activity in both vehicle-treated and ANG II-hypertensive rats (control: Delta-44 +- 15% vs. ANG II: Delta-41 +- 10%).	dibutyryl-cGMP	13-27	solute carrier family 12 member 1	Rattus norvegicus	52-57
26887831-9	2016	In contrast, dibutyryl-cGMP significantly decreased NKCC2 activity in both vehicle-treated and ANG II-hypertensive rats (control: Delta-44 +- 15% vs. ANG II: Delta-41 +- 10%).	dibutyryl-cGMP	13-27	angiotensinogen	Rattus norvegicus	95-101